Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  670 results for "%22AUSTRALIA%22"

Your Filters

Publisher : elsevier Subject : biomarkers Subject : diabetes mellitus, type 2 Subject : glucose intolerance Subject : insulin-secreting cells Subject : renal insufficiency, chronic Filter by : Author
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.

  • Authors : Chan KW; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Division of Nephrology, Department of Medicine, The University of Hong Kong, Hong Kong SAR

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/complications

  • Source: Kidney international [Kidney Int] 2023 Dec; Vol. 104 (6), pp. 1219-1226. Date of Electronic Publication: 2023 Aug 31.Publisher: Elsevier Country of Publication: United States NLM ID: 0323470 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.

  • Authors : Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands; The George Institute for Global Health, Sydney, NSW, Australia. Electronic address: .

Subjects: Atrial Fibrillation*/Atrial Fibrillation*/Atrial Fibrillation*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/complications

  • Source: Lancet (London, England) [Lancet] 2023 Nov 25; Vol. 402 (10416), pp. 2004-2017. Date of Electronic Publication: 2023 Nov 03.Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials.

  • Authors : Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; The George Institute for Global Health, Sydney, Australia. Electronic address: .

Subjects: Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy; Humans

  • Source: Kidney international [Kidney Int] 2023 Jul; Vol. 104 (1), pp. 181-188. Date of Electronic Publication: 2023 Apr 28.Publisher: Elsevier Country of Publication: United States NLM ID: 0323470 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Differences between HbA 1c and glucose-related variables in predicting weight loss and glycaemic changes in individuals with overweight and hyperglycaemia - The PREVIEW trial.

  • Authors : P Silvestre M; Human Nutrition Unit, School of Biological Sciences, Department of Medicine, University of Auckland, Auckland, New Zealand; CINTESIS, NOVA Medical School, NMS, Universidade Nova de Lisboa, 1169-056, Lisboa, Portugal. Electronic address: .

Subjects: Hyperglycemia* ; Prediabetic State* ; Glucose Intolerance*

  • Source: Clinical nutrition (Edinburgh, Scotland) [Clin Nutr] 2023 May; Vol. 42 (5), pp. 636-643. Date of Electronic Publication: 2023 Mar 07.Publisher: Elsevier Country of Publication: England NLM ID: 8309603 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.

  • Authors : Rossing P; Steno Diabetes Center Copenhagen, Copenhagen, Denmark; University of Copenhagen, Copenhagen, Denmark. Electronic address: .

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/diagnosis ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/therapy

  • Source: Kidney international [Kidney Int] 2022 Nov; Vol. 102 (5), pp. 990-999.Publisher: Elsevier Country of Publication: United States NLM ID: 0323470 Publication Model: Print Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Kynurenine-3-monooxygenase expression is activated in the pancreatic endocrine cells by diabetes and its blockade improves glucose-stimulated insulin secretion.

  • Authors : Liu J; Laboratoire B2PE (Biologie et Pathologie du Pancréas Endocrine), Unité BFA (Biologie Fonctionnelle et Adaptive), CNRS UMR 8251, Université Paris-Cité, Paris, France; Shandong Institute of Endocrine and Metabolic Diseases, Shandong First Medical University, Jinan, Shandong, China

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/metabolism ; Insulin-Secreting Cells*/Insulin-Secreting Cells*/Insulin-Secreting Cells*/metabolism; Animals

  • Source: Biochimica et biophysica acta. Molecular basis of disease [Biochim Biophys Acta Mol Basis Dis] 2022 Nov 01; Vol. 1868 (11), pp. 166509. Date of Electronic Publication: 2022 Jul 29.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101731730 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.

  • Authors : Smeijer JD; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, the Netherlands.; Koomen J

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetic Nephropathies*/Diabetic Nephropathies*/Diabetic Nephropathies*/complications

  • Source: JACC. Heart failure [JACC Heart Fail] 2022 Jul; Vol. 10 (7), pp. 498-507. Date of Electronic Publication: 2022 May 04.Publisher: Elsevier Country of Publication: United States NLM ID: 101598241 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Testosterone, Diabetes Risk, and Diabetes Prevention in Men.

  • Authors : Yeap BB; Medical School, University of Western Australia, Perth, Western Australia 6009, Australia; Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, Western Australia 6150, Australia. Electronic address: .

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/etiology ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/prevention & control

  • Source: Endocrinology and metabolism clinics of North America [Endocrinol Metab Clin North Am] 2022 Mar; Vol. 51 (1), pp. 157-172. Date of Electronic Publication: 2022 Feb 08.Publisher: Elsevier Country of Publication: United States NLM ID: 8800104 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/complications

  • Source: Kidney international [Kidney Int] 2022 Jan; Vol. 101 (1), pp. 174-184. Date of Electronic Publication: 2021 Sep 22.Publisher: Elsevier Country of Publication: United States NLM ID: 0323470 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Chagas disease is not associated with diabetes, metabolic syndrome, insulin resistance and beta cell dysfunction at baseline of Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).

  • Authors : Resende BAM; Internal Medicine Department, Faculty of Medicine, Faculdade Atenas, Sete Lagoas, Minas Gerais, Brazil.; Beleigoli AMR

Subjects: Insulin Resistance*; Chagas Disease/Chagas Disease/Chagas Disease/*epidemiology ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*epidemiology

  • Source: Parasitology international [Parasitol Int] 2021 Dec; Vol. 85, pp. 102440. Date of Electronic Publication: 2021 Aug 17.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9708549 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
  • 1-10 of  670 results for "%22AUSTRALIA%22"